

**Outcome of twin-twin transfusion syndrome according to the Quintero stage of the disease:
a systematic review and meta-analysis**

Daniele Di Mascio,^{1,2} Asma Khalil,^{3,4} Alice D'Amico,⁵ Danilo Buca,⁵ Pierluigi Benedetti Panici,¹ Maria Elena Flacco,⁶ Lamberto Manzoli,⁶ Marco Liberati,⁵ Luigi Nappi⁷, Vincenzo Berghella,² Francesco D'Antonio⁷

1: Department of Maternal and Child Health and Urological Sciences, Sapienza University of Rome, Italy
2: Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, USA
3: Fetal Medicine Unit, Saint George's Hospital, London, United Kingdom
4: Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute, St George's University of London, United Kingdom
5: Department of Obstetrics and Gynecology, University of Chieti, Italy
6: Department of Medical Sciences, University of Ferrara, Italy
7: Fetal Medicine and Cardiology Unit, Department of Obstetrics and Gynecology, Department of Medical and Surgical Sciences, University of Foggia, Italy

Corresponding Author:

Francesco D'Antonio, MD, PhD
Department of Obstetrics and Gynecology
Department of Medical and Surgical Sciences
University of Foggia
Viale Luigi Pinto
71100 Foggia, Italy
francesco.dantonio@unifg.it

Short title: Outcome of TTTS by stage of disease

Keywords: twin-twin transfusion syndrome; TTTS; Quintero staging system; twins; monochorionic twin pregnancy

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/uog.22054

Contribution

What are the novel findings of this work?

The present study represents the most and comprehensive review of the outcomes of TTTS according to Quintero staging system. The overall survival in MCDA pregnancies complicated by TTTS is higher at earlier Quintero stages (I-II) than stage III and IV. Neurological morbidity occurred in about 10% of all cases and was higher in stage II, III and IV.

What are the clinical implications of this work?

Further RCTs are needed to elucidate the optimal management of stage I TTTS.

Laser therapy is currently the best available approach for stage II-IV TTTS as perinatal survival rates are still satisfying even at stage III and IV, particularly when considering at least one survivor

ABSTRACT

Objectives: To report the outcomes of twin-twin transfusion syndrome (TTTS) according to Quintero staging system.

Methods: Medline, Embase and Cinahl databases were searched for studies reporting outcomes of TTTS stratified by Quintero staging (I-V). The primary outcome was the survival rate according to TTTS stage. The secondary outcomes were gestational age at birth (weeks), preterm birth (PTB) <34, 32 and 28 weeks of gestation and neonatal morbidity. Outcomes were reported according to different management options (expectant, laser therapy or amnioreduction) for stage I, including only cases treated with laser therapy for stages II-IV and only those managed expectantly for stage V. Random-effect head-to-head meta-analyses were used to analyze the extracted data.

Results: Twenty-six studies (2699 twin pregnancies) were included. 610 (22.6%) were diagnosed at Quintero stage I, 692 (25.6%) at stage II, 1146 (42.5%) at stage III, 247 (9.2%) at stage IV and 4 (0.1%) at stage V. Survival of at least one twin occurred in 86.9% (95% CI 84.0-89.7; 456 cases) of pregnancies at stage I, 85% (95% CI 79.1-90.1; 514 cases) at stage II, 80.6% (95% CI 75.7-85.1; 865 cases) at stage III, 82.8% (95% CI 73.6-90.4; 172 cases) at stage IV and 54.6% (95% CI 24.8-82.6; 5 cases) at stage V. The rate of pregnancies with no survivor was 11.8% (95% CI 8.4-15.8; 69 cases) at stage I, 15% (95% CI 9.9-20.9; 76 cases) at stage II, 18.6% (95% CI 14.2-23.4; 165 cases) at stage III, 17.2% (95% CI 9.6-26.4; 33 cases) at stage IV and 45.4% (95% CI 17.4-75.2; 4 cases) at stage V. Gestational age at birth was similar in stage I-III TTTS, and gradually decreases in stage IV and V. Overall, the incidence of PTB and neonatal morbidity increases as the severity of TTTS increases, but data on these two outcomes were limited by the small sample size of the included studies. When stratifying the analysis of stage I TTTS according to the type of intervention, perinatal survival of at least one twin was 84.9% (95% CI 70.4-95.1; 94 cases) in cases managed expectantly, 86.7% (95% CI 82.6-90.4; 249 cases) in those undergoing laser therapy and 92.2% (95% CI 84.2-97.6; 56 cases) in those after amnioreduction, while double survival was 67.9% (95% CI 57.0-77.9; 73 cases), 69.7% (95% CI 61.6-77.1; 203 cases) and 80.8% (95% CI 62.0-94.2; 49 cases) in the three groups, respectively.

Conclusion: The overall survival in MCDA pregnancies affected by TTTS is higher at earlier Quintero stages (I-II), but perinatal survival rates are reasonable even at stage III and IV when treated with laser therapy. Gestational age at birth was similar in stage I-III TTTS, and gradually decreases

in stage IV and V treated with laser. In pregnancies affected by stage I TTTS, amnioreduction was associated with a slightly higher survival compared to laser therapy and expectant management, although these findings might only be confirmed by future head-to-head, randomized trials.

Accepted Article

INTRODUCTION

Monochorionic (MC) twin pregnancies are at increased risk of perinatal mortality and morbidity compared to dichorionic (DC) gestations, mostly due to conditions arising from their peculiar placental vascular arrangement, such as twin-twin transfusion syndrome (TTTS), twin anemia-polycythemia (TAPS) and twin reverse arterial perfusion (TRAP) sequence.¹⁻¹¹

Although the pathophysiology of TTTS has not been fully elucidated yet, an unbalanced flow through the inter-twin vascular anastomoses are critical for the development of TTTS, leading to progressive hemodynamic derangements mainly consisting of cardiac overload of the recipient and chronic hypoperfusion and hypoxemia in the donor twin.^{2,12}

TTTS is commonly graded according to the ultrasound staging system proposed by Quintero in 1999 and consisting in five progressive stages characterized by the presence of oligohydramnios/polyhydramnios sequence (stage I), absent visualization of the donor's bladder (stage II), Doppler anomalies (stage III), fetal hydrops (stage IV) and eventually fetal demise of one or both twins (stage V).¹³ While the majority of stage I TTTS remains stable or regress even without intervention,¹⁴⁻¹⁵ fetoscopic laser ablation of placental anastomoses is the treatment of choice for stages II-IV TTTS.^{2,16} Anyway, data on perinatal mortality and morbidity stratified by Quintero staging system in monochorionic twin pregnancies affected by TTTS are still scant.

More recently, another classification system mainly focused upon the echocardiographic features of the recipient twin, known as the CHOP (Children's Hospital of Philadelphia) score, has been proposed to correlate with the Quintero staging system and clinical outcome of MC twins affected by TTTS, although its actual prognostic value is still debated.¹⁷⁻¹⁸

In general, the overall survival rates of 50-70% can be expected after fetoscopic laser for the treatment of TTTS, with a 30-50% chance of overall perinatal death and 5-20% chance of long-term neurological impairment.² However, these figures referred to the overall population of MC twins affected by TTTS, while the occurrence of the different adverse outcome according to the individual stage of the disease has not been consistently reported yet.

The aim of this systematic review was to report the outcome of TTTS according to the Quintero stage of the disease.

METHODS

Protocol, information sources and literature search

This review was performed according to an a-priori designed protocol and recommended for systematic reviews and meta-analysis.¹⁹⁻²¹ Medline and Embase databases were searched electronically on October 2019 utilizing combinations of the relevant medical subject heading (MeSH) terms, key words, and word variants for “twin-twin transfusion syndrome”, “monochorionic pregnancies”, “ultrasound” and “outcome”. The search and selection criteria were restricted to English language. Reference lists of relevant articles and reviews were hand searched for additional reports. Prisma guidelines were followed.²²⁻²⁴ The study was registered with the PROSPERO database (registration number: CRD42020150971).

Outcomes measures, study selection and data collection

The primary outcome was the survival rate, defined as:

- No survival: defined as death of both twins before birth
- Single survivor: defined as the survival to birth of only one twin
- Double survival: defined as survival to birth of both twins
- Survival of at least one twin

Secondary outcomes were:

- Gestational age at birth (expressed in weeks)
- Respiratory morbidity (including respiratory distress syndrome, transient tachypnoea of the new-born, continuous positive airway pressure for at least 24 hours, mechanical ventilation, need for supplemental oxygen, pulmonary hypertension or bronchopulmonary dysplasia)
- Neurological morbidity (including seizures, intra-ventricular haemorrhage and periventricular leukomalacia of any grade detected on ultrasound scan)
- Severe neurological morbidity (including seizures, intra-ventricular haemorrhage grade III and IV and periventricular leukomalacia grades II and III detected on ultrasound scan)
- Composite morbidity, defined as the occurrence of either of the morbidities
- Preterm birth (PTB) <34 weeks of gestation

- Preterm birth (PTB) <32 weeks of gestation
- Preterm birth (PTB) <28 weeks of gestation

All the explored outcomes were reported for monochorionic diamniotic (MCDA) twins according to the Quintero staging system of the disease,¹³ defined as:

- Stage I: defined as the presence of oligohydramnios (maximum vertical pocket, MVP <2 cm) in the donor and polyhydramnios (MVP>8 cm) in the recipient twin.
- Stage II: defined as the non-visualization of fetal bladder in donor twin over 60 minutes of observation.
- Stage III: defined upon the presence of Doppler abnormalities (absent or reversed umbilical artery diastolic flow, reversed ductus venosus a-wave flow, pulsatile umbilical vein flow).
- Stage IV: defined as the presence of hydrops in one or both twins.
- Stage V: defined as the occurrence of fetal demise in one or both twins.

We aimed to explore the occurrence of mortality and morbidity in the overall populations of twins and in the donor and recipient twin separately.

For pregnancies affected by stage I, we reported all the explored outcomes according to different management options (expectant management, laser therapy and amnioreduction). The reason for this choice was based upon the fact that the optimal management for these pregnancies has still to be ascertained.¹⁴ For stage II-IV TTTS, only studies reporting the outcome of pregnancies treated with laser were considered suitable for the inclusion in the current systematic review. Finally, for cases affected by stage V, we report the outcome only for those cases managed expectantly. Studies including higher order multiple gestations, those including monochorionic monoamniotic (MCMA) twin pregnancies, structural or chromosomal anomalies and those from which data the observed outcomes stratified by the stage of the disease could not be extrapolated were excluded. Studies published before 2000 were also excluded, as we considered that advances in prenatal imaging techniques, improvements in the diagnosis and treatment of TTTS make them less relevant. Only full text articles were considered eligible for the inclusion; case reports, conference abstracts and case series with fewer than 5 cases were excluded in order to avoid publication bias.

Two authors (DDM, ADA) reviewed all abstracts independently. Agreement regarding potential relevance was reached by consensus. Full text copies of those papers were obtained, and the same two reviewers independently extracted relevant data regarding study characteristics and pregnancy outcome. Inconsistencies were discussed by the reviewers and consensus reached or by discussion with a third author. If more than one study was published for the same cohort with identical endpoints, the report containing the most comprehensive information on the population was included to avoid overlapping populations.

Quality assessment, risk of bias and statistical analysis

Quality assessment of the included studies was performed using the Newcastle-Ottawa Scale (NOS) for cohort studies. According to NOS, each study is judged on three broad perspectives: the selection of the study groups; the comparability of the groups; and the ascertainment of the outcome of interest.²⁵ Assessment of the selection of a study includes the evaluation of the representativeness of the exposed cohort, selection of the non-exposed cohort, ascertainment of exposure and the demonstration that the outcome of interest was not present at start of study. Assessment of the comparability of the study includes the evaluation of the comparability of cohorts on the basis of the design or analysis. Finally, the ascertainment of the outcome of interest includes the evaluation of the type of the assessment of the outcome of interest, length and adequacy of follow-up. According to NOS a study can be awarded a maximum of one star for each numbered item within the Selection and Outcome categories. A maximum of two stars can be given for Comparability.

Random-effect meta-analyses of proportions were used to combine data. For the purpose of the analysis, the denominator was represented by the number of twins per each group for the computation of survivors and morbidity, while the number of pregnancies for the assessment of PTB and the presence of at least one and two survivors. Funnel plots displaying the outcome rate from individual studies versus their precision (1/standard error) were carried out with an exploratory aim. Tests for funnel plot asymmetry were not used when the total number of publications included for each outcome was less than ten. In this case, the power of the tests is too low to distinguish chance from real asymmetry.²⁶⁻²⁷

Between-study heterogeneity was explored using the I^2 statistic, which represents the percentage of between-study variation that is due to heterogeneity rather than chance. A value of 0% indicates no observed heterogeneity, whereas I^2 values of $\geq 50\%$ indicate a substantial level of heterogeneity. All analyses were performed using StatsDirect Statistical Software (StatsDirect Ltd Cambridge, United Kingdom).

RESULTS

Study selection and characteristics

1455 articles were identified, 60 were assessed with respect to their eligibility for inclusion and 26 studies²⁸⁻⁵³ were included in the systematic review (Table 1, Figure 1, Supplementary Table 1).

These 26 studies included 2699 MCDA twin pregnancies affected by TTTS. Gestational age at diagnosis of TTTS was reported only by ten studies.^{28,30,32-33,38-39,41,46,48,52} Out of the 2699 pregnancies affected by TTTS, 610 (22.6%) were diagnosed at Quintero stage I, 692 (25.6%) at stage II, 1146 (42.5%) at stage III, 247 (9.2%) at stage IV and 4 (0.1%) at stage V.

Stage I TTTS were treated with laser therapy in 62.4% (285/457 pregnancies), amnioreduction in 13.1% (60/457 pregnancies) and expectant management in 24.5% (112/457 pregnancies) of cases, respectively.

The majority of stage II-IV TTTS were treated with laser therapy, except for one study³⁰ which evaluated the outcome of expectant management even at higher stages of the disease; three studies^{40,41,52} in which TTTS was treated with amnioreduction and/or septostomy; one study⁵⁰ in which both laser therapy and amnioreduction were performed for stage II-IV TTTS. In stage V TTTS, one study³⁰ evaluated the outcome of expectant management, while the other one⁵² does not specify whether expectant management or amnioreduction and/or septostomy were performed.

The results of the quality assessment of the included studies using the NOS scale are presented in Table 2. Most of the included studies showed an overall good score regarding the selection and comparability of study groups, and for ascertainment of the outcome of interest. The main weaknesses of these studies were their retrospective design, small sample size and heterogeneity of outcomes observed. Furthermore, studies reporting information of morbidity were affected by the very small number of included cases and even smaller number of events, thus making it difficult to extrapolate objective evidence on the actual incidence of this outcome in the different stages of the disease.

Synthesis of the results

Stage I

Sixteen studies^{28,29-31,33,35,37-40,42,46,48,51-53} reported information on stage I TTTS.

There was no survival of either twin in 11.8% of pregnancies affected by stage I TTTS (95% CI 8.4-15.8; 69/564), while one and two survivors were reported in 17.5% (95% CI 14.4-20.9; 95/560) and

70% (95% CI 65.4-74.4; 396/560) of cases, respectively. At least one twin survived in 86.9% of pregnancies (95% CI 84-89.7; 456/522) (Table 3; Figure 2).

Mean gestational age at delivery was 31.1 weeks (95% CI 29.9-32.2) (Table 4; Supplementary Figure S1a). PTB <34 and <32 weeks of gestation complicated 50% (95% CI 12.6-98.7; 1/2), and 27.1% (95% CI 13.9-42.8; 9/34) of pregnancies complicated by stage I TTTS, respectively, while there was no case of PTB <28 weeks of gestation among the included cases (Table 5).

Three studies reported data on neonatal morbidity.^{32,46,53} Composite morbidity was reported in 22.9% (95% CI 0.1-68.49; 44/188) twins affected by stage I TTTS, neurological and respiratory morbidity complicated 1.5% (95% CI 0.02-5.1; 2/148) and 19.1% (95% CI 11.3-29.1; 16/84) of twins after birth (Table 6).

When stratified the analysis according to the different management options - expectant, laser therapy or amnioreduction - the mean gestational age at diagnosis was 21.0, 21.4 and 23.5 weeks of gestation, respectively (Supplementary Table 2). No twin survived to birth in 15.1% (95% CI 4.9-29.6; 18/112) in those cases managed expectantly, in 13.2% (95% CI 9.6-17.4; 36/285) of those having laser treatment and in 7.8% (95% CI 2.5-15.8; 4/60) of those undergoing amnioreduction. Survival of at least one twin was reported in 84.9% (95% CI 70.4-95.1; 94/112) of cases managed expectantly, 86.7% (95% CI 82.6-90.4; 249/285) of those having laser therapy and in 92.2% (95% CI 84.2-97.6; 56/60) of those undergoing amnioreduction. Conversely, it was not possible to perform a comprehensive pooled data synthesis on the occurrence of morbidity according to different management options in view of the very small number of studies exploring this outcome (Table 7; Figure 3).

Stage II

Fourteen studies^{29,31,34-38,42-44,49,50,51,53} reported information on stage II TTTS.

There was no survival of either twin in 15.0% (95% CI 9.9-20.9; 76/590) of pregnancies, while one and two survivors were reported in 22.4% (95% CI 17.6-27.7; 123/590) and 66.4% (95% CI 52.6-69.9; 391/590) of cases, respectively. At least one survivor was reported in 85.0% (95% CI 79.1-90.1; 514/590) of pregnancies affected by TTTS and treated with laser therapy (Table 3; Figure 2).

Mean gestational age at treatment was 20.3, while mean gestational age at delivery was 31.4 weeks (29.5-33.3) (Table 4; Supplementary Table 3; Supplementary Figure S1b). PTB <34, <32 and 28

weeks of gestation occurred in 31.3% (95% CI 10.0-58.0; 4/12), 42.8% (95% CI 29.4-56.9; 20/47) and 17.6% (95% CI 1.6-45.3; 2/12) of pregnancies, respectively (Table 5).

Two studies reported data on neonatal morbidity.^{44,53} Overall, composite morbidity affected 28.8% (95% CI 6.8-97.0; 39/124) of twins after birth. Neurological morbidity occurred in 5.2% (95% CI 0.3-15.4; 6/124), while respiratory morbidity in 70.4% (95% CI 56.4-82.0; 38/54) of twins (Table 6).

Stage III

Fifteen studies^{29,31,34-38,42-45,49,50,51,53} reported information on stage III TTTS.

No survival was observed in 18.6% (95% CI 14.2-23.4; 165/1040) of twin pregnancies affected by stage III TTTS and treated with laser, while one and two survivors were reported in 35.0% (95% CI 29.3-40.8; 341/1040) and 45.4% (95% CI 38.2-52.7; 534/1040) of cases, respectively. At least one survivor was reported in 80.6% of pregnancies (95% CI 75.7-85.1; 865/1040) (Table 3; Figure 2).

Mean gestational age at treatment was 20.2, while mean gestational age at delivery was 31.4 weeks (30.0-32.7) (Table 4; Supplementary Table 3; Supplementary Figure S1c), while PTB <34, <32 and <28 weeks of gestations complicated 37.3% (95% CI 5.2-78.0; 12/30), 53.3% (95% CI 36.1-70.2; 32/58) and 9.7% (95% CI 2.0-22.3; 3/30) of cases, respectively (Table 5).

Two studies reported data on neonatal morbidity.^{44,53} Composite morbidity affected 29.3% (95% CI 18.6-91.8; 48/127) twins after stage III TTTS. Finally, neurological and respiratory morbidity were reported in 6.7% (95% CI 2.9-12.1; 8/127) and 64.8% (95% CI 52.5-75.8; 46/71) of twins after birth (Table 6).

Stage IV

Fifteen studies^{29,31,34-38,42-45,49,50,51,53} reported data on stage IV TTTS.

There was no survival of either twin in 17.2% of pregnancies (95% CI 9.6-26.4; 33/205), while one and two survivors were reported in 27.7% (95% CI 21.9-33.9; 55/205) and 53.7% (95% CI 40.2-66.8; 117/205) of cases, respectively. At least one survivor was reported in 82.8% of pregnancies (95% CI 73.6-90.4; 172/205) (Table 3; Figure 2).

Mean gestational age at treatment was 21.4, while mean gestational age at delivery was 29.9 weeks (28.5-31.4) weeks (Table 4; Supplementary Table 3; Supplementary Figure S1d), while PTB <34 and

<32 weeks of gestation was reported in 46.5% (95% CI 15.5-79.2; 3/7), 59.9% (95% CI 37.9-80.0; 11/18), while there was no pregnancy delivered <28 weeks (PP: 0, 95% CI 0-30.7; 0/7) (Table 5). Two studies reported data on neonatal morbidity.^{44,53} Composite neonatal morbidity complicated 24.1% (95% CI 0.02-71.8; 21/64) of twins after birth, while neurological and respiratory morbidity were reported in 5.9% (95% CI 1.6-13.0; 3/64), and 47.6% (95% CI 32.0-63.6; 20/42) of cases, respectively (Table 6).

Stage V

Outcome ascertainment of MC twin pregnancies affected by stage V TTTT was affected by the very small number of included cases (9 pregnancies) and even smaller number of events, with only two studies^{30,52} reporting information of the outcomes observed in the present systematic review.

Death of the co-twin occurred in 45.4% of pregnancies (95% CI 17.4-75.2; 4/9), while the remaining twin survived in 54.6% (95% CI 24.8-82.6; 5/9) of cases (Table 3; Figure 2).

Mean gestational age at delivery was 26.5 (24.4-28.5) weeks (Table 4; supplementary figure S1e), while there was no study reporting data on morbidity and on the incidence of PTB at different gestational age windows.

Sub-group analyses

It was not possible to perform a comprehensive pooled data synthesis on the incidence of mortality and morbidity in the donor and recipient twin separately and according to the gestational age at occurrence of the TTTS due to the very small number of included studies reporting these data.

DISCUSSION

Main findings

The findings from this systematic review show that the perinatal survival of twin pregnancies complicated by TTTS seems to be higher in the first stages (I and II) of the disease, although it remains high even in its later phases (stage III and IV). Conversely, the perinatal mortality is higher in stage V. Gestational age at birth was similar in stage I-III TTTS, and gradually decreases in stage IV and V. Overall, the incidence of PTB and neonatal morbidity increases as the severity of TTTS increases, but these data were limited by the small sample size of the included studies.

When considering the different management options in pregnancies complicated by stage I TTTS (expectant management, laser therapy or amnioreduction) the perinatal survival of at least one twin was similar, thus making it difficult to extrapolate a robust evidence on the optimal type of intervention when stage I TTTS is diagnosed.

Strengths and limitations

The small number of cases in some of the included studies, their retrospective non-randomized design, lack of standardized criteria for the antenatal surveillance, management and timing of delivery of MCDA twin pregnancies complicated by TTTS represent the major limitations of this systematic review. Furthermore, some of the included studies reported data on the outcomes of stage II-IV TTTS treated with different management options - even though fetoscopic laser therapy is currently the gold standard for this subset of pregnancies – and it was not always possible to extrapolate information on cases treated with laser therapy only. It was not possible to draw any convincing evidence on stage V TTTS or on neonatal morbidity due to the negligible number of cases evaluated in this review. Another major limitation of the present review was the lack of stratification of the analysis according to the cardiovascular status of the affected twins, that previous studies have claimed as a potential predictor of the outcome of pregnancies affected by TTTS, irrespective of the Quintero stage. Unfortunately, the large majority of these studies did not report information according to TTTS different stages, thus making it impossible to integrate such information in the outcome ascertainment. Finally, we could not explore the effect of individual Doppler indices in affecting the outcome of twins undergoing laser as this information was not provided by the large majority of included studies.

Interpretation of findings and comparison with other published evidence

The findings from this study are in line with those reported in 2016 by Khalil et al¹⁴ in terms of overall survival in Quintero stage I TTTS, but differ from the above-mentioned meta-analysis and a previous systematic review by Rossi and D'Addario¹⁵ when stratifying outcomes according to the type of intervention. When focusing on higher Quintero stages treated with laser therapy, our results in terms of perinatal survival are concordant with those reported in the most recent and largest series⁵⁴⁻⁵⁶ that showed a double survival rate ranging between 50-65% and that of at least one twin survival of 75-90% at stage II-IV. Likewise, our findings are also consistent with a recent systematic review reporting perinatal outcome of pregnancies affected by TTTS treated with laser therapy over the past 25 years, in which the double survival rate was 62%, while at least one survivor was reported in up to 88% in the subgroup analysis of studies published between 2011 and 2014.⁵⁷

Our results showed similar incidence of neonatal neurological morbidity at birth, compared with a previous meta-analysis by Rossi et al who reported an incidence of less than 10% and was comparable at Quintero stage II-IV, while it was lower at stage I.⁵⁸

Clinical and research implications

While laser therapy is considered the gold standard for stage II-IV TTTS,² the optimal management for Quintero stage I TTTS is still a matter of debate, as there are no published randomized controlled trials (RCT) exploring different management options.

The findings from this review showed that, although perinatal survival of at least one twin was almost similar among the three management options, amnioreduction was associated with a slightly higher survival of both twins and lower chance of double fetal loss. These results should be interpreted with caution because the included studies were not designed to compare these strategies and were not powered for most of the observed outcomes. Amnioreduction is not exempt of procedure-related complications, such as unintended septostomy, preterm premature rupture of membranes, abruption or infection,² and the rate of progression of stage I TTTS was reported to be 30% when amnioreduction was the first-line therapy, compared with none in pregnancies treated with laser.¹⁵ Further head-to-head RCTs are needed in order to elucidate the optimal management in pregnancies affected by stage I TTTS.

Fetoscopic selective laser ablation of anastomotic vessels followed by equatorial dichorionization (the Solomon technique) is currently recommended as the best available approach to treat stage II-IV TTTS between 16 and 26 weeks of gestation.² Our review showed that the overall survival was higher at earlier Quintero stages (I-II), and the perinatal survival rates were still satisfying even at stage III and IV.

In the present study, respiratory and neurological morbidities were intuitively lower at stage I TTTS (any management), while increased at stage II-IV (treated with laser), with respiratory morbidity affecting the majority of twins and neurological morbidity impairing up to 9% of newborns. The etiology of cerebral morbidity is still uncertain, as neurodevelopmental outcome was shown to be similar in monochorionic twins treated with laser therapy and dichorionic control subjects, thus leading to the hypothesis that neurological impairment could rather represent a detrimental effect which is inherent in prematurity.⁵⁹

Conclusion

The overall survival in MCDA pregnancies complicated by TTTS is higher at earlier Quintero stages (I-II) than stage III and IV. Gestational age at birth was similar in stage I-III TTTS, and gradually decreases in stage IV and V.

Further RCTs and long-term follow up studies are needed in order to elucidate the optimal management of pregnancies affected by stage I TTTS and to quantify the risk of neurological disability according to the severity of disease.

Acknowledgments

We thank Dr Edward Araujo and Dr Mauricio Mendes Barbosa for providing further information from their studies.

Funding

No funding was obtained for this systematic review.

Accepted Article

REFERENCES

1. Hayes EJ. Practice bulletin no. 169: multifetal gestations: twin, triplet, and higher-order multifetal pregnancies. *Obstet Gynecol* 2016; **128**: e131–e146.
2. Society for Maternal-Fetal Medicine, Simpson LL. Twin-twin transfusion syndrome. *Am J Obstet Gynecol* 2013; **208**:3-18.
3. Leombroni M, Liberati M, Fanfani F, Pagani G, Familiari A, Buca D, Manzoli L, Scambia G, Rizzo G, D'Antonio F. Diagnostic accuracy of ultrasound in detecting birthweight discordance in twin pregnancies: a systematic review and meta-analysis. *Ultrasound Obstet Gynecol.* 2017; **50**:442-450.
4. Buca D, Pagani G, Rizzo G, Familiari A, Flacco ME, Manzoli L, Liberati M, Fanfani F, Scambia G, D'Antonio F. Outcome in monochorionic twin pregnancies with selective intrauterine growth restriction according to the umbilical artery Doppler pattern of the smaller twin: a systematic review and meta-analysis. *Ultrasound Obstet Gynecol.* 2017; **50**:559-568.
5. D'Antonio F, Odibo A, Prefumo F, Khalil A, Buca D, Flacco M, Liberati M, Manzoli L, Acharya G. Weight discordance and perinatal mortality in twin pregnancies: a systematic review and meta-analysis. *Ultrasound Obstet Gynecol.* 2018; **52**:11-23.
6. D'Antonio F, Odibo A, Berghella V, Khalil A, Kack K, Saccone G, Prefumo F, Buca D, Liberati M, Pagani G, Acharya G. Systematic review and meta-analyses of monoamniotic twin pregnancies: Perinatal mortality, timing of delivery and prenatal management. *Ultrasound Obstet Gynecol.* 2019 **53**:166-174.
7. Di Mascio D, Acharya G, Khalil A, Odibo A, Prefumo F, Liberati M, Buca D, Manzoli L, Flacco ME, Brunelli R, Benedetti Panici P, D'Antonio F. Birthweight discordance and neonatal morbidity in twin pregnancies: a systematic review and meta-analysis. *Acta Obstet Gynecol Scand.* 2019; **98**:1245-1257.
8. Murgano D, Khalil A, Prefumo F, Van Mieghem T, Rizzo G, Heyborne K, Melchiorre K, Peeters S, Lewi L, Familiari A, Lopriore E, Oepkes D, Murata M, Anselem O, Buca D, Liberati M, Hack K, Nappi L, Baxi L, Scambia G, Acharya G, D'Antonio F. Outcome of twin-to-twin transfusion-syndrome in monochorionic monoamniotic twin pregnancies: a systematic review and meta-analysis. *Ultrasound Obstet Gynecol.* 2019 Oct 8.

9. Saccone G, Khalil A, Thilaganathan B, Glinianaia SV, Berghella V, D'Antonio F; MONOMONO; NorSTAMP; STORK research collaboratives. Weight discordance and perinatal mortality in monoamniotic twin pregnancies: analysis of the MONOMONO, NorSTAMP and STORK multiple pregnancy cohorts. *Ultrasound Obstet Gynecol*. 2019 May 27.
10. MONOMONO Working Group. Inpatient vs outpatient management and timing of delivery of uncomplicated monochorionic monoamniotic twin pregnancy: the MONOMONO study. *Ultrasound Obstet Gynecol*. 2019; **53**:175-183.
11. Pagani G, D'Antonio F, Khalil A, Papageorgiou A, Bhide A, Thilaganathan B. Intra-fetal laser treatment for twin reversed arterial perfusion sequence: cohort study and meta-analysis. *Ultrasound Obstet Gynecol*. 2013; **42**:6-14.
12. Kontopoulos E, Chmait RH, Quintero RA. Twin-to-twin transfusion syndrome: definition, staging, and ultrasound assessment. *Twin Res Hum Genet*. 2016; **19**:175–183.
13. Quintero RA, Morales WJ, Allen MH, Bornick PW, Johnson PK, Kruger M. Staging of twin-twin transfusion syndrome. *J Perinatol*. 1999; **19**:550–555.
14. Khalil A, Cooper E, Townsend R, Thilaganathan B. Evolution of Stage 1 Twin-to-Twin Transfusion Syndrome (TTTS): Systematic Review and Meta-Analysis. *Twin Res Hum Genet* 2016; **19**:207-216.
15. Rossi AC, D'Addario V. Survival outcomes of twin-twin transfusion syndrome stage I: a systematic review of literature. *Am J Perinatol* 2013; **30**:5-10.
16. Berghella V, Kaufmann M. Natural history of twin-twin transfusion syndrome. *J Reprod Med* 2001; **46**:480-484.
17. Rychik J, Tian Z, Bebbington M, Xu F, McCann M, Mann S, Wilson RD, Johnson MP. The twin-twin transfusion syndrome: spectrum of cardiovascular abnormality and development of a cardiovascular score to assess severity of disease. *Am J Obstet Gynecol* 2007; **197**:392.e1–e8.
18. Stirnemann JJ, Nasr B, Proulx F, Essaoui M, Ville Y. Evaluation of the CHOP cardiovascular score as a prognostic predictor of outcome in twin-twin transfusion syndrome after laser coagulation of placental vessels in a prospective cohort. *Ultrasound Obstet Gynecol* 2010; **36**:52-57.
19. Henderson LK, Craig JC, Willis NS, Tovey D, Webster AC. How to write a Cochrane systematic review. *Nephrology (Carlton)* 2010; **15**: 617-624.

20. NHS Centre for Reviews and Dissemination. Systematic reviews: CRD's guidance for undertaking reviews in health care. University of York: York (UK), 2009. Available at: https://www.york.ac.uk/media/crd/Systematic_Reviews.pdf. Retrieved December 3, 2016.
21. Welch V, Petticrew M, Petkovic J, Moher D, Waters E, White H, Tuqwell P. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration. *J Clin Epidemiol* 2016; **70**: 68-89.
22. Moher D, Liberati A, Tetzlaff J, Altman DG, and the PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *Ann Intern Med* 2009; **151**: 264–269.
23. Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S; PRISMA harms group. PRISMA harms checklist: improving harms reporting in systematic reviews. *BMJ* 2016; **352**: i157.
24. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. *JAMA* 2000; **283**: 2008–2012.
25. Newcastle-Ottawa Scale for assessing the quality of nonrandomised studies in meta- analyses. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
26. Hunter JP, Saratzis A, Sutton AJ, Boucher RH, Sayers RD, Bown MJ. In meta-analyses of proportion studies, funnel plots were found to be an inaccurate method of assessing publication bias. *J Clin Epidemiol*. 2014; **67**: 897-903.
27. Manzoli L, De Vito C, Salanti G, D'Addario M, Villari P, Ioannidis JP. Meta-analysis of the immunogenicity and tolerability of pandemic influenza A 2009 (H1N1) vaccines. *PLoS One*. 2011; **6**: e24384.
28. Washburn EE, Sparks TN, Gosnell KA, Rand L, Gonzalez JM, Feldstein VA. Stage I Twin-Twin Transfusion Syndrome: Outcomes of Expectant Management and Prognostic Features. *Am J Perinatol*. 2018; **35**:1352-1357.
29. Barbosa MM, Martins Santana EF, Milani HJF, Elito Júnior J, Araujo Júnior E, Moron AF, Nardoza LMM. Fetoscopic laser photocoagulation for twin-to-twin transfusion syndrome

treatment: initial experience in tertiary reference center in Brazil. *Obstet Gynecol Sci.* 2018; **61**:461-467.

30. Duryea EL, Happe SK, McIntire DD, Dashe JS. The natural history of twin-twin transfusion syndrome stratified by Quintero stage. *J Matern Fetal Neonatal Med.* 2016; **29**:3411-3415.
31. Chang YL, Chao AS, Chang SD, Hsieh PC, Su SY, Chen KJ, Cheng PJ, Wang TH. Outcome of twin-twin transfusion syndrome treated by laser therapy in Taiwan's single center: role of Quintero staging system. *Taiwan J Obstet Gynecol.* 2016; **55**:700–704.
32. Hinch E, Henry A, Wilson I, Welsh AW. Outcomes of stage I TTTS or liquor discordant twins: a single-centre review. *Prenat Diagn.* 2016; **36**:507-514.
33. Emery SP, Hasley SK, Catov JM, Miller RS, Moon-Grady AJ, Baschat AA, Johnson A, Lim FY, Gagnon AL, O'Shaughnessy RW, Ozcan T, Luks FI, North American Fetal Therapy Network. North American Fetal Therapy Network: intervention vs expectant management for stage I twin-twin transfusion syndrome. *Am J Obstet Gynecol.* 2016; **215**:346.e341–.e347.
34. Eschbach SJ, Boons LS, Wolterbeek R, Middeldorp JM, Klumper FJCM, Lopriore E, Oepkes D, Haak MC. Prediction of single fetal demise after laser therapy for twin-twin transfusion syndrome. *Ultrasound Obstet Gynecol.* 2016; **47**:356–362.
35. Has R, Kalelioglu I, Corbacioglu Esmer A, Ermis H, Dural O, Dogan Y, Yasa C, Yumru H, Demir O, Yuksel A, Ibrahimoglu L, Yildirim A. Stage-related outcome after fetoscopic laser ablation in twin-to-twin transfusion syndrome. *Fetal Diagn Ther.* 2014; **36**:287-292.
36. Ruano R, Rodo C, Peiro JL, Shamshirsaz AA, Haeri S, Nomura ML, Salustiano EMA, de Andrade KK, Sangi-Haghpeykar H, Carreras E, Belfort MA. Fetoscopic laser ablation of placental anastomoses in twin-twin transfusion syndrome using Solomon technique. *Ultrasound Obstetrics Gynecol.* 2013; **42**:434–439.
37. Swiatkowska-Freund M, Pankrac Z, Preis K. Results of laser therapy in twin-to-twin transfusion syndrome: our experience. *J Matern Fetal Neonatal Med.* 2012; **25**:1917-1920.
38. Chmait RH, Kontopoulos EV, Korst LM, Llanes A, Petisco I, Quintero RA. Stage-based outcomes of 682 consecutive cases of twin-twin transfusion syndrome treated with laser surgery: the US Fetus experience. *Am J Obstet Gynecol.* 2011; **204**:393.e391-e396.

39. Bebbington MW, Tiblad E, Huesler-Charles M, Wilson RD, Mann SE, Johnson MP. Outcomes in a cohort of patients with Stage I twin-to-twin transfusion syndrome. *Ultrasound Obstet Gynecol* 2010; **36**:48-51.
40. Fichera A, Lanna M, Fratelli N, Rustico M, Frusca T. Twin-to-twin transfusion syndrome presenting at early stages: is there still a possible role for amnioreduction? *Prenat Diagn*. 2010; **30**:144-148.
41. Korpraphong S, Tanawattanacharoen S. Outcome of pregnancies complicated by twin-twin transfusion syndrome in King Chulalongkorn Memorial Hospital. *J Med Assoc Thai*. 2010; **93**:1137-1144.
42. Meriki N, Smoleniec J, Challis D, Welsh AW. Immediate outcome of twin-twin transfusion syndrome following selective laser photocoagulation of communicating vessels at the NSW Fetal Therapy Centre. *Aust N Z J Obstet Gynaecol* 2010; **50**:112-119.
43. Morris RK, Selman TJ, Harbidge A, Martin WI, Kilby MD. Fetoscopic laser coagulation for severe twin-to-twin transfusion syndrome: factors influencing perinatal outcome, learning curve of the procedure and lessons for new centres. *BJOG*. 2010; **117**:1350-1357.
44. Cincotta RB, Gray PH, Gardener G, Soong B, Chan FY. Selective fetoscopic laser ablation in 100 consecutive pregnancies with severe twin-twin transfusion syndrome. *Aust N Z J Obstet Gynaecol*. 2009; **49**:22-27.
45. Ruano R, Brizot ML, Liao AW, Zugaib M. Selective fetoscopic laser photocoagulation of superficial placental anastomoses for the treatment of severe twin-twin transfusion syndrome. *Clinics*. 2009; **64**:91-96.
46. Wagner MM, Lopriore E, Klumper FJ, Oepkes D, Vandenbussche FP, Middeldorp JM. Short- and long-term outcome in stage 1 twin-to-twin transfusion syndrome treated with laser surgery compared with conservative management. *Am J Obstet Gynecol*. 2009; **201**:286.e1-6.
47. Middeldorp JM, Sueters M, Lopriore E, Klumper FJ, Oepkes D, Devlieger R, Kanhai HH, Vandenbussche FP. Fetoscopic laser surgery in 100 pregnancies with severe twin-to-twin transfusion syndrome in the Netherlands. *Fetal Diagn Ther*. 2007; **22**:190-194.
48. O'Donoghue K, Cartwright E, Galea P, Fisk NM. Stage I twin-twin transfusion syndrome: rates of progression and regression in relation to outcome. *Ultrasound Obstet Gynecol*. 2007; **30**:958-964.

49. Sepulveda W, Wong AE, Dezerega V, Devoto JC, Alcalde JL. Endoscopic laser surgery in severe second-trimester twin-twin transfusion syndrome: a three-year experience from a Latin American center. *Prenat Diagn.* 2007; **27**:1033-1038.
50. Gray PH, Cincotta R, Chan FY, Soong B. Perinatal outcomes with laser surgery for twin-twin transfusion syndrome. *Twin Res Hum Genet.* 2006; **9**:438–443.
51. Huber A, Diehl W, Bregenzer T, Hackeloer BJ, Hecher K. Stage-related outcome in twin-twin transfusion syndrome treated by fetoscopic laser coagulation. *Obstet Gynecol.* 2006; **108**:333–337.
52. Duncombe GJ, Dickinson JE, Evans SF. Perinatal characteristics and outcomes of pregnancies complicated by twin–twin transfusion syndrome. *Obstet Gynecol* 2003; **101**: 1190–1196.
53. Quintero RA, Dickinson JE, Morales WJ, Bornick PW, Bermúdez C, Cincotta R, Chan FY, Allen MH. Stage-based treatment of twin-twin transfusion syndrome. *Am J Obstet Gynecol.* 2003; **188**:1333–1340.
54. Persico N, Fabietti I, D'Ambrosi F, Riccardi M, Boito S, Fedele L. Postnatal survival after endoscopic equatorial laser for the treatment of twin-to-twin transfusion syndrome. *Am J Obstet Gynecol* 2016; **214**:533.e1-533.e7.
55. Rüegg L, Hüsler M, Krähenmann F, Natalucci G, Zimmermann R, Ochsenein-Kölble N. Outcome after fetoscopic laser coagulation in twin–twin transfusion syndrome—is the survival rate of at least one child at 6 months of age dependent on preoperative cervical length and preterm prelabour rupture of fetal membranes? *J Matern Neonatal Med* 2018; **10**:1-9.
56. Stirnemann J, Djaafri F, Kim A, Mediouni I, Bussières L, Spaggiari E, Veluppillai C, Lapillonne A, Kermorvant E, Magny JF, Colmant C, Ville Y. Preterm premature rupture of membranes is a collateral effect of improvement in perinatal outcomes following fetoscopic coagulation of chorionic vessels for twin-twin transfusion syndrome: A retrospective observational study of 1092 cases. *BJOG* 2018; **125**:1154–1162.
57. Akkermans J, Peeters SH, Klumper FJ, Lopriore E, Middeldorp JM, Oepkes D. Twenty-five years of fetoscopic laser coagulation in twin-twin transfusion syndrome: a systematic review. *Fetal Diagn Ther* 2015; **38**:241-253.

58. Rossi AC, Vanderbilt D, Chmait RH. Neurodevelopmental outcomes after laser therapy for twin-twin transfusion syndrome: a systematic review and meta-analysis. *Obstet Gynecol* 2011; **118**:1145-1150.
59. Lenclen R, Ciarlo G, Paupe A, Bussieres L, Ville Y. Neurodevelopmental outcome at 2 years in children born preterm treated by amnioreduction or fetoscopic laser surgery for twin-to-twin transfusion syndrome: comparison with dichorionic twins. *Am J Obstet Gynecol* 2009; **201**:291.e1-291.e5.

Figure legends

Figure 1. Systematic review flowchart

Figure 2. Stage I-V TTTS survival rate bar chart

Figure 3. Stage I TTTS survival rate according to different management options bar chart

Author	Year	Country	Study design	Period considered	GA at diagnosis*	GA at treatment*	Outcomes observed	Pregnancies (n)
Washburn ²⁸	2018	USA	Retrospective	2006-2016	20.8 (3.7)	No treatment	GA at birth, mortality	30
Carbosa ²⁹	2018	Brazil	Prospective	2012-2016	NR	20.7 (2.9)	GA at birth, PTB, mortality	24
Dalyea ³⁰	2016	USA	Retrospective	1997-2013	24 (17-21)	No treatment	GA at birth, mortality	20
Chang ³¹	2016	China	Retrospective	2005-2014	NR	20.6 (2.7)	GA at birth, mortality	100
Hinch ³²	2016	Australia	Retrospective	2007-2013	20.7 (19-23.1)	NR	GA at birth, mortality, morbidity	28
Emery ³³	2016	USA	Retrospective	2005-2014	21.5 (2.7)	NR	GA at birth, mortality	124
van der Meulen ³⁴	2016	The Netherlands	Retrospective	2007-2013	NR	19.7 (17.9-22.2)	GA at birth, mortality	
Has ³⁵	2014	Turkey	Retrospective	2006-2013	NR	21 (16-26)	GA at birth, mortality	85
Mano ³⁶	2013	Spain-USA-Brazil	Retrospective	2010-2012	NR	20 (15.4-26)	Mortality	102
Swiatkowska-Freund ³⁷	2012	Poland	Prospective	2005-2010	NR	20 (16-26)	Mortality	94
Chmait ³⁸	2011	USA	Prospective	2002-2010	20.6 (2.4)	NR	GA at birth, mortality	682
Robbington ³⁹	2010	USA	Retrospective	2005-2006	20.9 (0.4)	No treatment	GA at birth, mortality	42
Ficher ⁴⁰	2010	Italy	Retrospective	1999-2006	NR	21.4 (19.3-24.5)	Mortality	34
Korpraphong ⁴¹	2010	Thailand	Retrospective	2000-2009	22.9 (15-32)	No treatment	Mortality	25
Meril ⁴²	2010	Australia	Retrospective	2003-2008	NR	20 (16-25)	Mortality	79
Morris ⁴³	2010	United Kingdom	Prospective	2004-2009	NR	20.2 (18-22)	GA at birth, mortality	164
Cincotta ⁴⁴	2009	Australia	Prospective	2002-2007	NR	21 (18-28)	GA at birth, mortality, morbidity	100
Quano ⁴⁵	2009	Brazil	Prospective	2006-2008	NR	22 (19-26)	GA at birth, mortality	19
Wagner ⁴⁶	2009	The Netherlands	Retrospective	2000-2007	21	21.2 (2.6)	GA at birth, mortality	50
Middeldorp ⁴⁷	2007	Belgium-The Netherlands	Prospective	2000-2004	NR	20 (16-26)	GA at birth, mortality	100
O'Donoghue ⁴⁸	2007	United Kingdom	Retrospective	2000-2006	21.3 (15.4-31.5)	No treatment	GA at birth, mortality	46

Sepulveda ⁴⁹	2007	Chile	Prospective	2003-2006	NR	21 (17-25)	GA at birth, PTB, mortality	33
Gray ⁵⁰	2006	Australia	Retrospective	1994-2003	NR	20 (19-22)	Mortality	58
Haber ⁵¹	2006	Germany	Prospective	1999-2003	NR	20.7 (15.9-25.3)	GA at birth, mortality	200
Duncombe ⁵²	2004	Australia	Prospective	1992-2002	22.1 (19.7-25.4)	NR	GA at birth, mortality	69
Quintero ⁵³	2003	USA	Prospective	NR	NR	21.1	PTB, mortality, morbidity	173

Table 1. General characteristics of the included studies.

GA, gestational age; NR, not reported; PTB, preterm birth; *: data reported as mean (standard deviations) or median (range).

Table 2. Quality assessment of the included studies according to Newcastle-Ottawa Scale (NOS) for cohort studies; a study can be awarded a maximum of one star for each numbered item within the Selection and Outcome categories. A maximum of two stars can be given for Comparability.

Author	Year	Selection	Comparability	Outcome
Washburn ²⁸	2018	★★★	★	★★
Barbosa ²⁹	2018	★★★	★	★★
Duryea ³⁰	2016	★★★	★	★★
Chang ³¹	2016	★★★	★	★★
Hinch ³²	2016	★★★	★	★★
Emery ³³	2016	★★★	★	★★
Eschbach ³⁴	2016	★★★	★	★★
Has ³⁵	2014	★★★	★	★★
Ruano ³⁶	2013	★★★	★	★★
Swiatkowska-Freund ³⁷	2012	★★★	★	★★
Chmait ³⁸	2011	★★★	★	★★
Bebbington ³⁹	2010	★★★	★	★★
Fichera ⁴⁰	2010	★★★	★	★★
Korpraphong ⁴¹	2010	★★★	★	★★
Meriki ⁴²	2010	★★★	★	★★
Morris ⁴³	2010	★★★	★	★★
Cincotta ⁴⁴	2009	★★★	★	★★
Ruano ⁴⁵	2009	★★★	★	★★
Wagner ⁴⁶	2009	★★★	★	★★
Liddeldorp ⁴⁷	2007	★★★	★	★★
O'Donoghue ⁴⁸	2007	★★★	★	★★
Sepulveda ⁴⁹	2007	★★★	★	★★

Gray ⁵⁰	2006	★★★	★	★★
Huber ⁵¹	2006	★★★	★	★★
Duncombe ⁵²	2004	★★★	★	★★
Quintero ⁵³	2003	★★★	★	★★

Table 3. Pooled proportions for single and double survival in MCDA twin pregnancies affected by TTTS according to the stage of the disease. (95% confidence intervals, CI, between parentheses).

Outcome	Studies (n)	Fetuses (n/N)	Raw proportions (95% CI)	I ² (%)	Pooled Proportions (95% CI)
Stage I					
No survivor	16	69/564	11.3 (8.8-14.1)	36.1	11.8 (8.4-15.8)
One survivor	15	95/560	16.9 (14.0-20.3)	3.6	17.5 (14.4-20.9)
At least one survivor	15	456/522	87.4 (84.2-90.1)	0.3	86.9 (84.0-89.7)
Two survivors	15	396/560	70.7 (66.8-74.5)	18.4	70.0 (65.4-74.4)
Stage II					
No survivor	14	76/590	12.9 (10.4-15.8)	65.4	15.0 (9.9-20.9)
One survivor	14	123/590	20.6 (17.8-24.3)	43.5	22.4 (17.6-27.7)
At least one survivor	14	514/590	87.1 (84.2-89.6)	65.4	85.0 (79.1-90.1)
Two survivors	14	391/590	54.1 (50.0-58.1)	74	66.4 (52.6-69.9)
Stage III					
No survivor	15	165/1040	15.9 (13.8-18.2)	65.8	18.6 (14.2-23.4)
One survivor	15	341/1040	32.8 (30.0-35.7)	66.9	35.0 (29.3-40.8)
At least one survivor	15	865/1040	83.2 (80.8-85.3)	66	80.6 (75.7-85.1)
Two survivors	15	534/1040	51.4 (48.3-54.4)	78.4	45.4 (38.2-52.7)
Stage IV					
No survivor	15	33/205	16.1 (11.7-21.8)	56.3	17.2 (9.6-26.4)
One survivor	15	55/205	26.9 (21.2-33.9)	0	27.7 (21.9-33.9)

At least one survivor	15	172/205	83.9 (78.6-88.3)	56.3	82.8 (73.6-90.4)
Two survivors	15	117/205	57.1 (50.2-63.7)	70.2	53.7 (40.2-66.8)
Stage V					
No survivor	2*	4/9	44.4 (18.0-73.3)	0	45.4 (17.4-75.2)
One survivor	2*	5/9	55.6 (26.7-81.1)	0	54.6 (24.8-82.6)

*one study³⁰ evaluated the outcome of expectant management, while the other one⁵² does not specify whether expectant management or amnioreduction and/or septostomy were performed.

Table 4. Mean gestational age at birth in MCDA twin pregnancies affected by TTTS, according to the stage of the disease. Weighted means were obtained combining data from individual studies to perform meta-analyses of single-group continuous data. For the sake of completeness, raw means were also reported. (CI = Confidence Interval).

Disease stage	Studies (n)	Fetuses (Total sample)	Raw mean (95% CI)	Weighted mean (95% CI)	I² (%)
Stage I	13	527	30.9 (28.9-32.9)	31.1 (29.9-32.2)	87.4
Stage II	11	437	31.4 (29.9-32.9)	31.4 (29.5-33.3)	91.7
Stage III	12	750	31.3 (30.0-32.7)	31.4 (30.0-32.7)	87.2
Stage IV	12	170	30.1 (28.5-31.8)	29.9 (28.5-31.4)	47.3
Stage V	2	4	26.7 (22.2-31.1)	26.5 (24.4-28.5)	0

Table 5. Pooled proportions for morbidity in MCDA twins affected by TTTS according to the stage of the disease. (95% confidence intervals, CI, between parentheses).

Outcome	Studies (n)	Fetuses (n/N)	Raw proportions (95% CI)	I ² (%)	Pooled Proportions (95% CI)
Stage I					
PTB <34 weeks	1	1/2	50.0 (12.6-98.7)	-	-
PTB <32 weeks	2	9/34	26.5 (12.9-44.4)	0	27.1 (13.9-42.8)
PTB <28 weeks	1	0/2	0.0 (0-84.2)	-	-
Stage II					
PTB <34 weeks	2	4/12	33.3 (9.9-65.1)	72.3	31.3 (10.0-58.0)
PTB <32 weeks	3	20/47	42.6 (28.3-57.8)	0	42.8 (29.4-56.9)
PTB <28 weeks	2	2/12	16.7 (2.1-48.4)	17.7	17.6 (1.6-45.3)
Stage III					
PTB <34 weeks	2	12/30	40.0 (22.7-59.4)	82.6	37.3 (5.2-78.0)
PTB <32 weeks	3	32/58	55.2 (41.5-68.3)	44.3	53.3 (36.1-70.2)
PTB <28 weeks	2	3/30	10.0 (2.1-26.5)	68.1	9.7 (2.0-22.3)
Stage IV					
PTB <34 weeks	2	3/7	42.9 (9.9-81.6)	73.8	46.5 (15.5-79.2)
PTB <32 weeks	3	11/18	61.1 (35.7-82.7)	0	59.9 (37.9-80.0)
PTB <28 weeks	2	0/7	0.0 (0-41.0)	0	0.0 (0-30.7)
Stage V					
PTB <34 weeks	-	-	-	-	-
PTB <32 weeks	-	-	-	-	-
PTB <28 weeks	-	-	-	-	-

Table 6. Pooled proportions for morbidity in MCDA twins affected by TTTS according to the stage of the disease. (95% confidence intervals, CI, between parentheses).

Outcome	Studies (n)	Fetuses (n/N)	Raw proportions (95% CI)	I² (%)	Pooled Proportions (95% CI)
Stage I					
Composite morbidity	3	44/188	23.4 (17.6-30.19)	97.7	22.9 (0.1-68.49)
Neurological morbidity (overall)	2	2/148	1.4 (1.6-4.8)	42.8	1.5 (0.02-5.1)
Severe neurological morbidity	2	2/84	2.4 (0.2-8.3)	-	-
Respiratory morbidity	1	16/84	19.1 (11.3-29.1)	-	-
Stage II					
Composite morbidity	2	39/124	31.5 (23.4-40.4)	98.9	28.8 (6.8-97.0)
Neurological morbidity (overall)	2	6/124	4.8 (1.8-10.2)	74.2	5.2 (0.3-15.4)
Severe neurological morbidity	1	5/54	9.3 (3.1-20.3)	-	-
Respiratory morbidity	1	38/54	70.4 (56.4-82.0)	-	-
Stage III					
Composite morbidity	2	48/127	37.8 (29.3-46.8)	98.5	29.3 (18.6-91.8)
Neurological morbidity (overall)	2	8/127	6.3 (2.8-12.0)	12.3	6.7 (2.9-12.1)
Severe neurological morbidity	1	6/71	8.5 (3.2-17.5)	-	-
Respiratory morbidity	1	46/71	64.8 (52.5-75.8)	-	-

Stage IV					
Composite morbidity	2	21/64	32.8 (21.6-45.7)	93.4	24.1 (0.02-71.8)
Neurological morbidity (overall)	2	3/64	4.7 (1.0-13.1)	0	5.9 (1.6-13.0)
Severe neurological morbidity	1	2/42	7.1 (1.5-19.5)	-	-
Respiratory morbidity	1	20/42	47.6 (32.0-63.6)	-	-
Admission to NICU					
Stage V					
Composite morbidity	-	-	-	-	-
Neurological morbidity (overall)	-	-	-	-	-
Severe neurological morbidity	-	-	-	-	-
Respiratory morbidity	-	-	-	-	-

Table 7. Pooled proportions for single and double survival in MCDA twin pregnancies affected by stage I TTTS according to different management options (expectant, laser and amnioreduction). (95% confidence intervals, CI, between parentheses).

Outcome	Studies (n)	Fetuses (n/N)	Raw proportions (95% CI)	I² (%)	Pooled Proportions (95% CI)
Stage I (expectant)					
No survivor	4	18/112	16.1 (9.8-24.2)	67	15.1 (4.9-29.6)
One survivor	3	18/108	16.7 (10.2-25.1)	0	17.5 (11.0-25.1)
At least one survivor	4	94/112	83.9 (75.8-90.2)	67	84.9 (70.4-95.1)
Two survivors	3	73/108	67.6 (57.9-76.3)	29.4	67.9 (57.0-77.9)
Stage I (laser therapy)					
No survivor	10	36/285	12.6 (9.0-17.1)	0	13.2 (9.6-17.4)

One survivor	10	46/285	16.1 (12.1-20.9)	0	16.7 (12.6-21.2)
At least one survivor	10	249/285	87.4 (82.9-91.0)	0	86.7 (82.6-90.4)
Two survivors	10	203/285	71.2 (65.6-76.4)	37.9	69.7 (61.6-77.1)
	Stage I (amnioreduction)				
No survivor	3	4/60	6.7 (1.8-16.2)	0	7.8 (2.5-15.8)
One survivor	3	7/60	11.7 (4.8-22.6)	62.1	12.9 (2.5-30.1)
At least one survivor	3	56/60	93.3 (83.8-98.2)	0	92.2 (84.2-97.6)
Two survivors	3	49/60	81.7 (69.6-90.5)	61.7	80.8 (62.0-94.2)



PRISMA 2009 Flow Diagram


Accepted Article

Identification

Screening

Eligibility

Included



From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit www.prisma-statement.org.

This article is protected by copyright. All rights reserved.





Figure 2

267x163mm (72 x 72 DPI)



Stage I TTTS survival rate according to different management options bar chart